Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease

To provide the best experiences, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent or withdrawal of consent may adversely affect certain features and functions.

Functional Always active

Storage or technical access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of transmitting a communication over an electronic communications network.

Preferences

Storage or technical access is necessary for the legitimate purpose of storing preferences not requested by the subscriber or user.

Statistics

Storage or technical access used exclusively for statistical purposes. Storage or technical access which is used exclusively for anonymous statistical purposes. In the absence of a subpoena, voluntary compliance by your Internet service provider or additional third-party records, information stored or retrieved for this sole purpose generally cannot be used to identify you.

Marketing

Storage or technical access is necessary to create user profiles in order to send advertisements, or to track the user on a website or on several websites with similar marketing purposes.